Antimicrobial therapy Flashcards

1
Q

Antimicrobial therapy - groups

A
  1. Cell wall synthesis
  2. Folic acid synthesis
  3. DNA topoisomerases
  4. Damage DNA
  5. mRNA synthesis
  6. Protein synthesis
  7. daptomycin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Antimicrobial therapy - Cell wall synthesis drugs - divided to

A
  1. Peptidogylcan synthesis drugs

2. Peptidoglycan cross linking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Antimicrobial therapy - peptidoglycan cross linking - Groups and drugs

A
  1. Penicillinae sensitive penicillins (amoxillin, ampicillin, Penicillin G and V)
  2. Penicillinase-resistant penicillins (Dicloxacillin, Nafcillin, Oxacillin, Methcillin)
  3. Antipseudomonals (Piperacillin, Ticarcillin)
  4. Cephalosporins (I-V)
  5. Carbapenems (Doripenem, Ertapenem, Imipenem, Meropenem)
  6. Monobactams (Aztreonam)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Antimicrobial therapy - Penicillinae sensitive penicillins - drugs

A
  1. amoxillin
  2. ampicillin
  3. Penicillin G and V
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Prototype β-lactam antibiotics

A

Penicillin G and V

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Penicillin G vs V

A

Penicillin G –> IV and IM form

Penicillin V –> Oral

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Penicillin G and V - mechanism of action

A

D-Ala-Ala analog –> Bind penicillin-binding proteins (transpeptidas) –> blocks trasnpeptisase cross linking of peptidoglycan in cell wall –> inhibits cell wall synthesis –> Activate autolytic enzyme
BACTERICIDAL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Penicillin G and V - clinical use

A

gram + cocci and robs, gram (-) cocci, spirochetes:

  1. gram (+) organisms (S. pneumoniae, S.pygoenes, Actinomyces)
  2. gram (-) cocci (mainly N. meningitidis)
  3. spirochetes (mainly T. pallidum)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Penicillin G and V - toxicity

A
  1. Hyperesensitivity reactions

2. Hemolytic anemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Penicillin G and V - resistance

A

Penicillinae in bacteria (a type of β-lactamase) cleaves β-lactam ring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

aminopenicillins - drugs

A
  1. amoxillin

2. ampicillin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

aminopenicillins (amoxicillin, ampicillin) - mechanism of action

A

same as penicillin but WIDER SPECTRUM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

aminopenicillins (amoxicillin, ampicillin) - clinical use

A
extended spectrum penicillin:
1. H. infl   2. H. pylori  3. E. coli 
4. Listeria  5. Proteus  6. Salmonella
7. Shigella  8.  Entetococci 
MNEMONIC : HHELPSS + enterococci
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

aminopenicillins (amoxicillin, ampicillin) - toxicity

A
  1. hypersensitivity reactions
  2. rash
  3. pseudomembranous colitis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

aminopenicillins (amoxicillin, ampicillin) - mechanism of resistance

A

penicillinase in bacteria (a type of β-lactamase) cleaves β-lactams ring–> combine with clavulanic acid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Penicillinase-resistant penicillins - drugs

A
  1. Dicloxacillin
  2. Nafcillin
  3. Oxacillin
  4. Methcillin
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Penicillinase-resistant penicillins - mechanism of action

A

same as penicillin

NARROW SPECTRUM AND PENICILLINASE RESISTANT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Penicillinase-resistant penicillins - mechanism of penicillinase resistance

A

Bulky R group blocks blocks access of β-lactase to lactam ring

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Penicillinase-resistant penicillins - drugs and clinical use

A
  1. Dicloxacillin2. Nafcillin 3. Oxacillin 4. Methcillin

S. aureus (except MRSA)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

MRSA - mechanism of resistance

A

altered penicillin binding protein target site

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Penicillinase-resistant penicillins - toxicity

A
  1. hypersensitivity reactions

2. interstitial nephritis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Antipseudomonals - drugs

A

Piperacillin, Ticarcillin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Antipseudomonals - mechansism of action

A

same as penicillin

Extended spectrum

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Antipseudomonals - clinical use

A
  1. psudomonas spp and gram-negative robs

2. gram (-) robs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Antipseudomonals - toxicity

A

hypersensitivity reaction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Antipseudomonals - resistance

A

susceptible to penicillinase –> use with β-lactamase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

β-lactamase inhibitors - drugs

A
  1. clavulanic acid
  2. sulbactam
  3. tazobactam
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

β-lactamase inhibitors - use

A

often added to penicillin antibiotics to protect the antibiotic from destruction by β-lactamase (penicillinase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

Cephalosporins - drugs

A

1st generation –> cefazolin, cephalexin
2nd generation –> cefoxitin, cefaclor, cefuroxamine
3rd generation –> ceftriaxone, cefotaxime, ceftazidime
4th generation –> cefepime
5th generation –> ceftraroline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

Cephalosporins - mechanism of action

A

β- lactam drugs that inhibit cell wall synthesis but are less susceptible to penicillinases - BACTERICIDAL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

organisms typically not covered by Cephalosporins?

A

mnemonic: LAME
Listeria, Atypicals (Chlamydia, Mycoplasma) MRSA, Entrococci
exception. Ceftaroline (5th) covers MRSA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

1st generation cephalosporins - drugs and clinical use

A
cefazolin, cephalexin 
1. gram + cocci 
2. Proteus
3. E. coli
4. Klebsiella 
cefazolin used prior to surgery to prevent S. aureus wound infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

cefazolin used prior to surgery to

A

prevent S. aureus wound infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

2nd generation - drugs and clinical use

A

cefoxitin, cefaclor, cefuroxamine

  1. like 1st generation (gram + cocci, proteus, E.coli, Klebsiella)
  2. H. infuenzae
  3. Enterobacter aerogenes
  4. Neisseria spp
  5. Serratia marcescens
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

3rd generation - drugs and clinical use

A

ceftriaxone, cefotaxime, ceftazidime
serious gram (-) infections resistant to other β-lactams
- ceftriaxone –> meningitis, gonnorrhea, disseminated Lyme disease
- Ceftazimide –> Pseudomonas

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

4th generation - drugs and clinical use

A

cefepime
gram (-) organism, with high activity against Pseudomonas
2. gram (+)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

5th generation - drugs and clinical use

A
ceftaroline
1. broad gram (+)
2. borad gram (-)
INCLUDING MRSA 
DOES NTO COVER PSEUDOMONAS
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

Cephalosporins - toxicity

A
  1. hypersensitivity reactions
  2. autoimmune hemolytic anemia
  3. disulfiram-like reaction
  4. vitamin K deficiency
  5. exhibit cross-reactivity with penicillins
  6. Increases aminoglycosides mediated nephrotoxicity
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

Cephalosporins - mechanise of resistance

A

structural change in penicillin-binding proteins (transpeptidase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

Carbapenems - drugs

A
  1. Imipenem
  2. Meropenem
  3. Doripenem (newer)
  4. Ertapenem (newer)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

Carbapenems - mechanism of action

A

broad spectrum, β-lactamase-resistant β-lactam
ALWAYS ADMINISTRATED WITH CILASTATIN (inhibitor of renal dehydropeptidase I) to decrease inactivation of drug in renal tubule –> meropenem is stable to cilastatin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

cilastatin - mechansim of action

A

inhibitor of renal dehydropeptidase I

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

Carbapenems - clinical use

A
  1. Gram (+) cocci
  2. Gram (-) robs
  3. anaerobes
    WIDE spectrum but significant side effects limit use of life threatening infection or after other drugs have failed
    Ertapenem has limited pseudomonas coverage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

Carbapenems - toxicity

A
  1. GI distress
  2. skin rash
  3. CNS toxicity (seizurs) at high plasma levels (less risk with meropenem)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

Monobactams - drugs

A

Aztreonam

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

Monobactams (Aztreonam) - mechansim of action

A

Bind penicillin-binding proteins 3 (transpeptidas) –> blocks trasnpeptisase cross linking of peptidoglycan in cell wall –> inhibits cell wall synthesis –> Activate autolytic enzyme
LESS SUSCEPTIBLE TO β-lactamases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

Monobactams (Aztreonam) - 2 special characteristics

A
  1. no cross-allergenicity with penicillins

2. Synergistic with aminoglycosides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

Monobactams (Aztreonam) - clinical use

A
  1. Gram (-) robs ONLY (no anaerobesm no gram (+))

For penicillin allergic patients and those with renal insufficiency who cannot tolerate aminoglycosides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

Monobactams (Aztreonam) - side effects

A

usually nontoxin –> occasional GI upset

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

Monobactams (Aztreonam) - β-lactamases

A

less susceptible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

Carbapenems (Doripenem, Ertapenem, Imipenem, Meropenem) - β-lactamases

A

resistant

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

Antimicrobial therapy - Cell wall synthesis drugs - divided to

A
  1. Peptidogylcan synthesis drugs

2. Peptidoglycan cross linking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

Antimicrobial therapy - Cell wall synthesis drugs - groups and drugs

A

glycopeptides:
1. Bacitracin
2. Vancomycin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
54
Q

Vancomycin - mechanism of action

A

inhibits cell wall peptidoglycan formation by binding D-ala D-ala portion of cell wall precursors
BACTERICIDAL
not susceptible to β-lactamases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
55
Q

Vancomycin - clinical use

A
gram (+)  bugs only:
serious Multidrug resistance organisms, including:
- MRSA 
- S. epidermidis 
- Clostiridium difficle (oral)
- Enterococcus species
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
56
Q

Vancomycin - toxicity

A

well tolerated

  1. nephrotoxicity
  2. ototoxicity
  3. thrombophlebitis
  4. red man syndrom (diffuse flushing)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
57
Q

red man syndrom - appearance, caused by, solution

A
  • diffuse flushing
  • it is caused by vancomycin
  • pretreatment with antihistamines and slow infusion rate
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
58
Q

Vancomycin - mechanism of resistance

A

occurs in bacteria via amino acid modification of D-ala D-ala to D-ala D-lac

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
59
Q

Antimicrobial therapy - DNA topoisomerases - drugs

A

Fluroroquinolones: (-FLOXACIN) + enoxacin

  1. CIPRO-
  2. NOR-
  3. LEVO-
  4. O-
  5. MOXI
  6. GEMI-
  7. ENOXACIN
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
60
Q

Fluroroquinolones - drug that i not -floxacin

A

enoxacin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
61
Q

Fluroroquinolones - mechanism of action

A

inhibit prokaryotic enzymes topoisomerase II (DNA gyrase) and topoisomerase IV
BACTERICIDAL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
62
Q

Fluororoquinolones - clinical use

A
  1. gram (-) robs of urinary and GI tracts (including Pseudomonas)
  2. Neisseria
  3. some gram (+)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
63
Q

Fluororoquinolones - toxicity

A
  1. GI upset
  2. superinfections
  3. skin rash
    4 .headache/dizziness
  4. leg cramps and myalgias (less commonly)
  5. Prolonged QT
  6. tendonitis or tendon rupture (if >60 or prednisone)
  7. contraindicated in pregnancy, nursing mothers, children under eighteen –> possible damage to cartilage
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
64
Q

Fluororoquinolones - mechanism of resistance

A
  1. chromosome encoded mutation in DNA gyrase
  2. plasmid mediated resistance
  3. efflux pumps
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
65
Q

Antimicrobial therapy - damage DNA drug

A

metronidazole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
66
Q

metronidazole - mechanism of action

A

Forms toxic free radical metavolites in the bacterial cell that damage DNA.
BACTERICIDAL, ANTIPROTOZOAL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
67
Q

metronidazole - clinical use

A
  1. Giardia
  2. Entamoeba
  3. Trichomonas vaginalis
  4. Garndenella vaginalis
  5. Anaerobes (Bacteroides, C. difficile)
  6. H. pylori
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
68
Q

metronidazole - adverse effects

A
  1. Disulfiram-like reaction (severe flushing, tachycardia, hypertension) with alcohol
  2. headache
  3. metallic taste
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
69
Q

Daptomycin - mechanism of action

A

lipopeptide that disrupt cell membrane of gram (+) cocci

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
70
Q

Daptomycin - clinical use

A
  1. S. aureus SKIN infection (esp MRSA)
  2. bacteremia
  3. endocarditis
  4. VRE
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
71
Q

Daptomycin to pneumonia

A

not used –> avidly binds to and is inactivated by surfactant

72
Q

Daptomycin - toxicity

A
  1. Myopathy

2. rhabdomyolysis

73
Q

Antimicrobial therapy - protein synthesis - divisions and drugs

A

50S –> 1. Chloramphenicol 2. Clindamycin 3. Linezolid 4. Macrolides 5. Streptogramins
30S –> 1. aminoglycosides 2. Tetracyclines

74
Q

Antimicrobial therapy - protein synthesis - mechanism of action

A

specifically target smaller bacterial ribosome (70S=30S+50S), leaving human ribosome (80S) unaffected

75
Q

Aminoglycosides - drugs

A
  1. Gentamycin
  2. Neomycin
  3. Amikacin
  4. Tobramycin
  5. Streptomycin
76
Q

Aminoglycosides - mechanism of action

A
  • irreversible inhibition of initiation complex through binding of the 30S subunit
  • mRNA misreading
  • Block translocation
    BACTEROCIDAL /REQUIRE O2 FOR UPTAKE
77
Q

Aminoglycosides - clinical use

A
  1. severe gram (-) rob infection
  2. Synergistic with β-lactam antibiotics
  3. Neomycin for bowel surgery
78
Q

Aminoglycosides - side effects

A
  1. nephrotoxicity (worse with cephalosporins)
  2. Neuromascular blockage
  3. Ototoxicity (esp with loop diuretics)
  4. Teratogen
79
Q

Aminoglycosides - ototoxicity espc with

A

loop diuretics

80
Q

Aminoglycosides - mechanism of resistance

A

Bacterial tranferase enzymes inactivate the drug by acetylation, phosphorylation, or adenylation

81
Q

Tetracyclines - drugs

A
  • CYCLINE
  • tetracycline
  • doxycycline
  • minomycline
82
Q

Tetracyclines - mechanism of action

A

bind 30S (A-site tRNA binding) and prevent attachment of aminoacyl-tRNA
BACTERIOSTATIC
LIMITED CNS PENETRATION

83
Q

Tetracyclines - cns

A

limited penetration

84
Q

doxycycline - special characteristic

A

it is fecally eliminated and can be used in patients with renal failure

85
Q

Tetracyclines - co-administrations

A

do not take tetracyclines with milk (Ca2+), antiacids (Ca2+ or Mg2+), pr iron-containing preparations –> divalent cations inhibit drug’s absorption in the gut

86
Q

Tetracyclines - clinical use

A
  1. Borrelia bugdorferi
  2. M. pneumoniae
  3. Rickettsia
  4. Chlamydia
  5. acne
  6. Ehrichiosis/Anaplasmosis
  7. Q fever
87
Q

Tetracyclines - effective against Rickettsia and chlamydia because of

A

their ability to accumulate intracellulary

88
Q

Tetracyclines - renal failure

A

doxycycline is fecally eliminated and can be used in patients with renal failure

89
Q

Tetracyclines - toxicity

A
  1. GI distress
  2. discoloration of teeth and inhibition of bone growth in children
  3. photosensitivity
  4. Contraindicated in pregnancy
90
Q

Tetracyclines - mechanism of resistance

A

decreased uptake or increased efflux out of bacterial cells by plasmid-encoded transport pumps

91
Q

Antimicrobial therapy - protein synthesis - 30S inhibitors (and bactericidal or bacteriostatic)

A
1. Aminoglycosides (bactericidal)
2 Tetracyclines (bacteriostatic)
92
Q

chloramphenicol - mechanism of action

A

block peptidyltranferase at 50S ribosomal subunit

Bacteriostatic

93
Q

chloramphenicol - clinical use

A
  1. meningitis (H. infl, N. meningitis, S. pneumoniae)
  2. Rocky Montain spoted fever (R. ricketsi)
    Limited use owing to toxicities but often still used in developing countries (low cost)
94
Q

chloramphenicol - toxicity

A
  1. anemia (dose dependent)
  2. aplastic anemia (dose independent)
  3. gray baby syndrome
95
Q

chloramphenicol - gray baby syndrome - mechanism

A

in premature infants because they lack liver UDP-glucuronyl tranferase

96
Q

chloramphenicol - mechanism of resistance

A

plasmid-encoded acetyltranferase inactivates the drug

97
Q

Clindamycin - mechanism

A

blocks peptide transfer (translocation) at 50S ribosomal subunit.
BACTERIOSTATIC

98
Q

Clindamycin - clinical use

A
  1. anaerobic infections in aspiration pneumonia, lung abscess, oral infection
  2. invasive A streptococcal infection
  3. Gardenella vaginalis
99
Q

metronidazole vs clincamycin according to clinical use

A

treats anaerobic infection below diaphragm with metronidazole and above diaphragm with clindamycin

100
Q

Clindamycin - toxicity

A
  1. pseudomembranous colitis
  2. fever
  3. diarrhea
101
Q

Oxalinezolid - drugs

A

Linezolid

102
Q

Linezolid - mechanism of action

A

it inhibits protein synthesis by binding to 50S subunit and preventing formation of the initiation complex

103
Q

Linezolid - clinical use

A

gram (+) species MRSA and VRE

104
Q

Linezolid - toxicity

A
  1. bone marrow suppression (esp thrmbocytopenia)
  2. peripheral neuropathy
  3. seretonin syndrome
105
Q

Linezolid - mechanism of resistance

A

point mutation of ribosomal RNA

106
Q

Macrolides - drugs

A
  1. Azythromycin
  2. Clarithromycin
  3. Erythromycin
107
Q

Macrolides - mechanism of action

A

bind to the 23S rRNA of the 50S ribosomal subunit
–> inhibit protein synthesis by blocking translocation
BACTERIOSTATIC

108
Q

Macrolides - clinical use

A
  1. Atypical pneumonias (Mycoplasma, chlamydia, legionalla
  2. STI (chlamydia)
  3. Gram (+) cocci (streptococcal infections in patients allergic to penicillin)
  4. B. pertusis
109
Q

Macrolides - resistance

A

methylation of 23S rRNA-binding site prevents binding of drug

110
Q

Macrolides - side effects

A
  1. GI uspet 2
  2. Arrhytmia (long QT)
  3. Acute cholestatic hepatitis
  4. Rash
  5. eosinophilia
  6. increased serum levels of theophyllines, oral anticoagulants
  7. inhibit P-450 (clarithromycin and erythrmicycin)
  8. contraindicated in pregnancy (embryotoxic)
111
Q

macolides - P-450

A

clarithromycin and erythrmicycin inhibit P-450

112
Q

Antimicrobial therapy - protein synthesis - divisions and drugs (bactericidal or bacteriostatic)

A

50S –> 1. Chloramphenicol (bacteriostatic) 2. Clindamycin (bacteriostatic) 3. Linezolid (variable) 4. Macrolides (bacteriostatic) 5. Streptogramins
30S –> 1. aminoglycosides (bactericidal 2. Tetracyclines (bacteriostatic)

113
Q

Streptogramins - drugs

A
  1. Dalfopristin

2. Quinupristin

114
Q

Antimicrobial therapy - Folic acid synthesis - drugs

A
  1. Sulfonamides: a. sulfadiazine b. sulfamethoxazole (SMX)
    c. sulfisoxazole
  2. Trimethoprim (or pyrimethamine)
  3. dapsone
115
Q

Tetrahydrofolic acid (THF) synthesis pathway

A
PABA + Pteridine --> Dihydropteroic acid (Dihydropteroate syntase) --> Didhydrofolic acid --> 
Tetrahydrofolic acid (THF) (Dihydrofolate reductase)
116
Q

Tetrahydrofolic acid (THF) can give rise to

A
  1. Purines (DNA, RNA)
  2. Thymidine (DNA)
  3. Methionine (Protein)
117
Q

Trimethoprim - mechanism of action

A

inhibits bacterial dihydrofolate reductase

BACTERIOSTATIC

118
Q

dihydrofolate reductase - action

A
Didhydrofolic acid --> 
Tetrahydrofolic acid (THF)
119
Q

Trimethoprim - clinical use

A

in combination with sulfonamides (TMP-SXM) –> seqential block of folate syntesis –>
1. UTI 2. Shigella 3. Salmonella 4. P. jorovecii (treatment and prophyaxis) 5. toxoplasmosis prophylaxis

120
Q

Trimethoprim - toxicity

A
  1. megaloblastic anemia
  2. leukopenia
  3. granulocytopenia
    MAY ALLEVIATE WITH SUPPLEMENTAL FOLINIC ACID
121
Q

Tetrahydrofolic acid (THF) synthesis pathway - PABA?

A

Para-aminobenzoic acid

122
Q

Tetrahydrofolic acid (THF) synthesis pathway

A
PABA + Pteridine --> Dihydropteroic acid (Dihydropteroate syntase) --> Didhydrofolic acid --> 
Tetrahydrofolic acid (THF) (Dihydrofolate reductase)
123
Q

Antimicrobial therapy - Folic acid synthesis - drugs

A
  1. Sulfonamides: a. sulfadiazine b. sulfamethoxazole (SMX)
    c. sulfisoxazole
  2. Trimethoprim (or pyrimethamine)
124
Q

Sulfonamides - drugs

A

a. sulfadiazine
b. sulfamethoxazole (SMX)
c. sulfisoxazole

125
Q

Sulfonamides - mechanism of action

A
PABA antimetobolites (analog) inhibit dihydropteroate synthase 
BACTERIOSTATIC (BACTERICIDAL when combined with trimethoprim)
126
Q

Sulfonamides - clinical use

A
  1. Gram-positives
  2. Gram-negatives
  3. Nocardia
  4. Chlamydia
  5. simple UTI (TRIPLE SULFAS or SMX)
127
Q

Sulfonamides - toxicity

A
  1. hypersensitivity 2. G6PD hemolysis
  2. nephrotoxicity (tumbulointestinal nephritis)
  3. photosensitivity 5. kernicterus (infants)
  4. displace other drug from albumin (eg. warfarin)
128
Q

Sulfonamides displaces other drugs from albumin - example

A

warfarin

129
Q

Sulfonamides - nephrotoxicity?

A

tumbulointestinal nephritis

130
Q

Sulfonamides - mechanism of resistance

A
  1. altered enzyme (bacterial dihydropteroate syntase)
  2. decreased uptake
  3. increased PABA synthesis
131
Q

Dapsone mechanism of action and side effects

A

similar to sulfonamides, but structurally distinct agent

Hemolysis if G6PD deficiency

132
Q

Dapsone clinical use

A
  1. Leprosy (leptromatous and tuberculoid)

2. Pneumocystis jorovecii prophylaxis

133
Q

botulism treatment

A

antitoxin

134
Q

pseudomembranous colitis - treatment

A

metronidazoleo or oral vancomycin

For recurrent cases, consider repeating prior regimen, fidaxomicin, or fecal microbiota transplant

135
Q

Listeria monocytogenes - treatment

A
  1. gastroenteritis is self limited

2. ampicillin in infants, immunocompromised, and the elderly as empirical treatment of meningitis

136
Q

actinomyces vs Nocardia according to treatment

A

MNEMONIC: SNAP –> Sulfa - Nocardia / Actinom - Penicillin
Acinomyces –> penicillin
Nocardia –> sulfonamides

137
Q

C. tetani - therapy

A

Prevent with tetanus vaccine

treat with antitoxin +/- vaccine booster and diazepam (for muscle spasms)

138
Q

neisseria gonococci vs neisseria meningitis - treatment

A

neisseria gonococci –> ceftriaxone + (azithromycin or doxycycline) for possible chlamydial coinfection
neisseria meningitis –> ceftraxone or penicillin G

139
Q

neisseria gonococci vs neisseria meningitis - prevention

A

neisseria gonococci –> condoms (for STD), erythromycin ointment (neonatal transmision)
neisseria meningitis –> Rifampin, ciprofloxacin or ceftriaxone prophylaxis in close contacts

140
Q

H. influenza - treatment/prophylaxis

A
  1. mucosal infection –> amoxicillin +/- clavulanate
  2. meningitis –> ceftriaxon.
    prophylaxis –> rifampin
141
Q

Legionella - treatment

A

macrolide or quinolone

142
Q

Pseudomonas aeroginosa - treatment

A
  1. extended spectrum β-lactams (eg piperacillin, ticarcillin, cafepime)
  2. Carbapenems (eg imipenem, meropenem)
  3. Monobactams (eg aztreonam)
  4. Fluoroquinolones (eg ciprofloxacin)
  5. Aminoglycosides (eg. gentamycin, tobramicin)
  6. For multidrug resistant stains –> colistin, polymyxin B
143
Q

typhoid fever - treatment

A

ceftriaxone or flouroquinolone

144
Q

Helicobacter pylori - treatment

A

MC initial treatment:

PROTON PUMP INHIBITOR + CLARITHROMYCIN + AMOXICILLIN (or metronidaxzole if penicillin allergy)

145
Q

Lyme disease - treatment

A
  1. doxycycline

2. ceftriaxone

146
Q

how to prevent congenital syphilis

A

treat mother early in pregnancy, as placental transmission occurs after first trimester

147
Q

patients with + culture of Streptococcus agalactiae –>

A

receive intrapartum penicillin for prophylaxis

148
Q

Gardnerella vaginalis - treatment

A

metronidazole or clindamycin

149
Q

Typhus treatment

A

all vector-borne illness - rash common and rash rare diseases –> doxycycline

150
Q

Q fever treatment

A

all vector-borne illness - rash common and rash rare diseases –> doxycycline

151
Q

Chlamydia - treatment

A

azythromycin (favored because in time treatment) or doxycycline

152
Q

Lymphogranuloma venereum - treatment

A

doxycycline

153
Q

Mycoplasma pneumoniae - treatment

A

macrolides, doxycycline, or fluoroquinolone

154
Q

antimicrobial prophylaxis - high risk for endocarditis and undergoing surgical or dental procedures

A

amoxicillin

155
Q

antimicrobial prophylaxis - exposure to gonorrhea

A

ceftriaxone

156
Q

antimicrodial prophylaxis -history of reccurent UTIs

A

TMP-SMX

157
Q

antimicrobial prophylaxis - exposure to meningococcal infection

A

ceftriaxone, ciprofloxacin or rifampin

158
Q

antimicrodial prophylaxis - Pregnant woman carrying group B strep

A

Penicillin G

159
Q

antimicrobial prophylaxis - prevention of gonococcal conjuctivitis in newborn

A

Erythomycin oitment

160
Q

antimicrobial prophylaxis - prevention of postsurgical infection due to S. aureus

A

Cefazolin

161
Q

antimicrobial prophylaxis - prophylaxis of strep pharyngitis in child with prior rheumatic fever

A

Benzathine penicillin G
or
oral penicillin V

162
Q

antimicrobial prophylaxis - Exposure to syphilis

A

Benzathine penicillin G

163
Q

antibiotic for bowel surgery

A

neomycin

164
Q

Antibiotics to avoid in pregnancy (and why)

A
  1. Sulfonamides –> Kernicterus
  2. Amniglycosides –> Ototoxicity
  3. Fluoroquinolones –> Cartilage damage
  4. macrolides –> embryotoxic
  5. tetracyclines –> DIscolored teeth, inhibiton of growth
  6. Chloramphenicol –> Gray babe syndrome
  7. Griseofluvin –> teratogenic
  8. Ribavirin (antiviral)
165
Q

non bacterial antibiotics to avoid in pregnancy

A
  1. Griseofluvin –> teratogenic

2. Ribavirin (antiviral)

166
Q

antibiotic that causes kernicterus if used during pregnancy

A

Sulfonamides

167
Q

Treatment of highly resistant bacteria

A

MRSA: vancomycin, daptomycin (esp skin), linezolid, tigecycline, ceftaroline
VRE: linezolid and streptogramins (quinupristin, dalfopristin)
Multidrug-resistant P. aeruginosa: polymixins B and E (Colistin)
Multidrug-resistant Acinetobacter baumannii: polymixins B and E (Colistin)

168
Q

Treatment of MRSA

A

vancomycin, daptomycin (esp skin), linezolid, tigecycline, ceftaroline

169
Q

treatment of VRE

A

linezolid and streptogramins (quinupristin, dalfopristin)

170
Q

treatment Multidrug-resistant P. aeruginosa

A

polymixins B and E (Colistin)

171
Q

treatment of Multidrug-resistant Acinetobacter baumannii

A

polymixins B and E (Colistin)

172
Q

antibiotics - prophylaxis in HIV patients (and why)

A

CD4 under 2 hundred –> TMP-SMX (pneumocysts)
CD4 under 1 hundred –> TMP-SXM (pneumocysts and toxoplasmosis)
CD4 under fifty –> Azithromycin or clarythromycin (M. avium complex)

173
Q

antibiotics - prophylaxis in HIV patients (and why) - under 2 hundred

A

TMP-SMX (pneumocysts)

174
Q

antibiotics - prophylaxis in HIV patients (and why) - under 1 hundred

A

TMP-SXM (pneumocysts and toxoplasmosis)

175
Q

antibiotics - prophylaxis in HIV patients (and why) - under fifty

A

Azithromycin or clarythromycin (M. avium complex)